Trial Information
Evaluation of Cirrhosis and Malignant Hepatic Lesions Using Novel MR Contrast Agents
Inclusion Criteria:
- Alpha-feto protein > 400 ng / mL or
- prior ultrasound with mass suspicious for hepatic malignancy or.
- clinical risk of hepatocellular carcinoma or
- prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma
Exclusion Criteria:
- Glomerulo-filtration rate < 50 mL/ min/1.73 m2 based on a creatinine measurement
within three months of the MR study
- Previous diagnosis of hepatic malignancy
- Any conditions that would discount the ability to have an MRI scan
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Principal Investigator
Rizwan Aslam, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
San Francisco VA Medical Center
Authority:
United States: Federal Government
Study ID:
10-03278
NCT ID:
NCT01341132
Start Date:
May 2011
Completion Date:
Related Keywords:
- Hepatocellular Carcinoma
- HCC
- Hepatocellular Carcinoma
- MRI
- Liver
- Carcinoma
- Fibrosis
- Carcinoma, Hepatocellular
Name | Location |
San Francisco VA Medical Center |
San Francisco, California 94110 |